Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D03UJT
|
||||
| Former ID |
DIB018207
|
||||
| Drug Name |
[3H](-)devapamil
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Discovery agent | Investigative | [1] | ||
| Structure |
|
Download2D MOL |
|||
| Formula |
C26H36N2O3
|
||||
| InChI |
InChI=1S/C26H36N2O3/c1-20(2)26(19-27,22-11-12-24(30-5)25(18-22)31-6)14-8-15-28(3)16-13-21-9-7-10-23(17-21)29-4/h7,9-12,17-18,20H,8,13-16H2,1-6H3/t26-/m0/s1
|
||||
| InChIKey |
VMVKIDPOEOLUFS-SANMLTNESA-N
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID | |||||
| Target and Pathway | |||||
| Target(s) | Cav1.1 | Target Info | Inhibitor (gating inhibitor) | [2] | |
| Voltage-dependent L-type calcium channel subunit alpha-1C | Target Info | Inhibitor (gating inhibitor) | [3] | ||
| KEGG Pathway | MAPK signaling pathway | ||||
| Calcium signaling pathway | |||||
| cGMP-PKG signaling pathway | |||||
| cAMP signaling pathway | |||||
| Cardiac muscle contraction | |||||
| Adrenergic signaling in cardiomyocytes | |||||
| Vascular smooth muscle contraction | |||||
| Circadian entrainment | |||||
| Long-term potentiation | |||||
| Retrograde endocannabinoid signaling | |||||
| Glutamatergic synapse | |||||
| Cholinergic synapse | |||||
| Serotonergic synapse | |||||
| GABAergic synapse | |||||
| Dopaminergic synapse | |||||
| Insulin secretion | |||||
| GnRH signaling pathway | |||||
| Oxytocin signaling pathway | |||||
| Type II diabetes mellitus | |||||
| Alzheimer's disease | |||||
| Amphetamine addiction | |||||
| Hypertrophic cardiomyopathy (HCM) | |||||
| Arrhythmogenic right ventricular cardiomyopathy (ARVC) | |||||
| Dilated cardiomyopathy | |||||
| NetPath Pathway | IL2 Signaling Pathway | ||||
| PANTHER Pathway | Alzheimer disease-amyloid secretase pathway | ||||
| Nicotinic acetylcholine receptor signaling pathway | |||||
| 5HT2 type receptor mediated signaling pathway | |||||
| Beta1 adrenergic receptor signaling pathway | |||||
| Beta2 adrenergic receptor signaling pathway | |||||
| Oxytocin receptor mediated signaling pathway | |||||
| Nicotine pharmacodynamics pathway | |||||
| PathWhiz Pathway | Muscle/Heart Contraction | ||||
| Reactome | Adrenaline,noradrenaline inhibits insulin secretion | ||||
| NCAM1 interactions | |||||
| Regulation of insulin secretion | |||||
| WikiPathways | Calcium Regulation in the Cardiac Cell | ||||
| Arrhythmogenic Right Ventricular Cardiomyopathy | |||||
| Alzheimers Disease | |||||
| NCAM signaling for neurite out-growth | |||||
| Integration of energy metabolism | |||||
| Nicotine Activity on Chromaffin Cells | |||||
| References | |||||
| REF 1 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2515). | ||||
| REF 2 | (-)-[3H]Desmethoxyverapamil, a novel Ca2+ channel probe. Binding characteristics and target size analysis of its receptor in skeletal muscle. FEBS Lett. 1984 Oct 29;176(2):371-7. | ||||
| REF 3 | Pharmacological, radioligand binding, and electrophysiological characteristics of FPL 64176, a novel nondihydropyridine Ca2+ channel activator, in cardiac and vascular preparations. Mol Pharmacol. 1991 Nov;40(5):734-41. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.